Respiratory syncytial virus infection

References

Key articles

Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502.Full text  Abstract

Committee on Infectious Diseases; American Academy of Pediatrics. Red book. 32nd ed. Elk Grove Village, IL: AAP; 2021.Full text

Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016 Sep;5(3):271-98.Full text  Abstract

American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug;134(2):415-20.Full text  Abstract

Modjarrad K, Giersing B, Kaslow DC, et al; WHO RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine. 2016 Jan 4;34(2):190-7.Full text  Abstract

Reference articles

1. Ralston SL, Lieberthal AS, Meissner HC, et al; American Academy of Pediatrics. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014 Nov;134(5):e1474-502.Full text  Abstract

2. National Center for Biotechnology Information. Taxonomy database: Pneumoviridae [internet publication].Full text

3. International Committee on Taxonomy of Viruses. Mononegavirales. Jul 2018 [internet publication].Full text

4. Hasegawa K, Goto T, Hirayama A, et al. Respiratory virus epidemiology among US infants with severe bronchiolitis: analysis of 2 multicenter, multiyear cohort studies. Pediatr Infect Dis J. 2019 Aug;38(8):e180-3.Full text  Abstract

5. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015 Feb 26;372(9):835-45.Full text  Abstract

6. Pneumonia Etiology Research for Child Health (PERCH) Study Group. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019 Aug 31;394(10200):757-79.Full text  Abstract

7. Committee on Infectious Diseases; American Academy of Pediatrics. Red book. 32nd ed. Elk Grove Village, IL: AAP; 2021.Full text

8. Bont L, Checchia PA, Fauroux B, et al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect Dis Ther. 2016 Sep;5(3):271-98.Full text  Abstract

9. Kuitunen I, Artama M, Mäkelä L, et al. Effect of social distancing due to the COVID-19 pandemic on the incidence of viral respiratory tract infections in children in Finland during early 2020. Pediatr Infect Dis J. 2020 Dec;39(12):e423-7.Full text  Abstract

10. Varela FH, Scotta MC, Polese-Bonatto M, et al. Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: likely role of lower transmission in the community. J Glob Health. 2021 Mar 1;11:05007.Full text  Abstract

11. Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 pandemic - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-9.Full text  Abstract

12. Tempia S, Walaza S, Bhiman JN, et al. Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020. Euro Surveill. 2021 Jul;26(29):2001600.Full text  Abstract

13. Ricart S, Marcos MA, Sarda M, et al. Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol. 2013 May;48(5):456-63.Full text  Abstract

14. Hall CB, Powell KR, MacDonald NE, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986 Jul 10;315(2):77-81. Abstract

15. Anderson EJ, Carbonell-Estrany X, Blanken M, et al. Burden of severe respiratory syncytial virus disease among 33-35 weeks' gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr Infect Dis J. 2017 Feb;36(2):160-7.Full text  Abstract

16. Carbonell-Estrany X, Fullarton JR, Gooch KL, et al. The influence of birth weight amongst 33-35 weeks gestational age (wGA) infants on the risk of respiratory syncytial virus (RSV) hospitalisation: a pooled analysis. J Matern Fetal Neonatal Med. 2017 Jan;30(2):134-40. Abstract

17. Mauskopf J, Margulis AV, Samuel M, et al. Respiratory syncytial virus hospitalizations in healthy preterm infants: systematic review. Pediatr Infect Dis J. 2016 Jul;35(7):e229-38.Full text  Abstract

18. Wang EE, Law BJ, Boucher FD, et al. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1996 Sep;129(3):390-5. Abstract

19. Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000 Dec;137(6):865-70. Abstract

20. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588-98.Full text  Abstract

21. Zhang Y, Yuan L, Zhang Y, et al. Burden of respiratory syncytial virus infections in China: systematic review and meta-analysis. J Glob Health. 2015 Dec;5(2):020417.Full text  Abstract

22. Shi T, McAllister DA, O'Brien KL, et al; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017 Sep 2;390(10098):946-58.Full text  Abstract

23. Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. Lancet Glob Health. 2019 Aug;7(8):e1031-45.Full text  Abstract

24. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): trends and surveillance. 18 Dec 2020 [internet publication].Full text

25. Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-83.Full text  Abstract

26. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004 Jan 15;189(2):233-8.Full text  Abstract

27. Colosia AD, Yang J, Hillson E, et al. The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: a systematic review. PLoS One. 2017 Aug 10;12(8):e0182321.Full text  Abstract

28. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59.Full text  Abstract

29. Sundaram ME, Meece JK, Sifakis F, et al. Medically attended respiratory syncytial virus infections in adults aged ≥50 years: clinical characteristics and outcomes. Clin Infect Dis. 2014 Feb;58(3):342-9.Full text  Abstract

30. Sieling WD, Goldman CR, Oberhardt M, et al. Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City. Influenza Other Respir Viruses. 2021 Jan 26:10.1111/irv.12842.Full text  Abstract

31. Shiley KT, Lautenbach E, Lee I. The use of antimicrobial agents after diagnosis of viral respiratory tract infections in hospitalized adults: antibiotics or anxiolytics? Infect Control Hosp Epidemiol. 2010 Nov;31(11):1177-83.Full text  Abstract

32. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 Sep 10;366:l5021.Full text  Abstract

33. Peters TR, Crowe JE Jr. Respiratory syncytial virus. In: Long SS, Pickering LK, Prober CG, eds. Principles and practice of pediatric infectious diseases. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2008.

34. Hall CB, Douglas RG Jr, Geiman JM. Quantitative shedding patterns of respiratory syncytial virus in infants. J Infect Dis. 1975 Aug;132(2):151-6. Abstract

35. Hall CB, Douglas RG Jr. Modes of transmission of respiratory syncytial virus. J Pediatr. 1981 Jul;99(1):100-3. Abstract

36. Hall CB, Douglas RG Jr, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis. 1980 Jan;141(1):98-102. Abstract

37. Hall CB, Douglas RG Jr, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J Pediatr. 1976 Jul;89(1):11-5. Abstract

38. Hoffman SJ, Laham FR, Polack FP. Mechanisms of illness during respiratory syncytial virus infection: the lungs, the virus and the immune response. Microbes Infect. 2004 Jul;6(8):767-72. Abstract

39. Johnson JE, Gonzales RA, Olson SJ, et al. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007 Jan;20(1):108-19.Full text  Abstract

40. Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Crit Care. 2006;10(4):R107.Full text  Abstract

41. Aherne W, Bird T, Court SD, et al. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol. 1970 Feb;23(1):7-18.Full text  Abstract

42. Patarčić I, Gelemanović A, Kirin M, et al. The role of host genetic factors in respiratory tract infectious diseases: systematic review, meta-analyses and field synopsis. Sci Rep. 2015 Nov 3;5:16119.Full text  Abstract

43. Zhou J, Zhang X, Liu S, et al. Genetic association of TLR4 Asp299Gly, TLR4 Thr399Ile, and CD14 C-159T polymorphisms with the risk of severe RSV infection: a meta-analysis. Influenza Other Respir Viruses. 2016 May;10(3):224-33.Full text  Abstract

44. Russell CD, Unger SA, Walton M, et al. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017 Apr;30(2):481-502.Full text  Abstract

45. Li Y, Pillai P, Miyake F, et al. The role of viral co-infections in the severity of acute respiratory infections among children infected with respiratory syncytial virus (RSV): a systematic review and meta-analysis. J Glob Health. 2020 Jun;10(1):010426.Full text  Abstract

46. Henderson FW, Collier AM, Clyde WA Jr., et al. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med. 1979 Mar 8;300(10):530-4. Abstract

47. Bradley JP, Bacharier LB, Bonfiglio J, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics. 2005 Jan;115(1):e7-14.Full text  Abstract

48. Cai W, Buda S, Schuler E, et al. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020 Nov;14(6):658-70.Full text  Abstract

49. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr. 1992 Sep;121(3):348-54. Abstract

50. Anderson J, Do LAH, Wurzel D, et al. Severe respiratory syncytial virus disease in preterm infants: a case of innate immaturity. Thorax. 2021 Sep;76(9):942-50. Abstract

51. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003 Nov;143(5 Suppl):S118-26. Abstract

52. National Institute for Health and Care Excellence. Bronchiolitis in children: diagnosis and management. Aug 2021 [internet publication].Full text

53. Wennergren G, Kristjánsson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur Respir J. 2001 Dec;18(6):1044-58.Full text  Abstract

54. Grut V, Söderström L, Naumburg E. National cohort study showed that infants with Down's syndrome faced a high risk of hospitalisation for the respiratory syncytial virus. Acta Paediatr. 2017 Jul 21;106(9):1519-24. Abstract

55. Chan M, Park JJ, Shi T, et al. The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: a systematic review and meta-analysis. J Glob Health. 2017 Dec;7(2):020413.Full text  Abstract

56. Beckhaus AA, Castro-Rodriguez JA. Down syndrome and the risk of severe RSV infection: a meta-analysis. Pediatrics. 2018 Sep;142(3):e20180225.Full text  Abstract

57. Mitra S, El Azrak M, McCord H, et al. Hospitalization for respiratory syncytial virus in children with Down syndrome less than 2 years of age: a systematic review and meta-analysis. J Pediatr. 2018 Dec;203:92-100.e3.Full text  Abstract

58. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Abstract

59. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532-40. Abstract

60. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011 Sep;12(5):580-8. Abstract

61. Pons JM, Tebé C, Paladio N, et al. Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection. Acta Paediatr. 2011 Mar;100(3):324-9. Abstract

62. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013;(4):CD006602.Full text  Abstract

63. Chiu SN, Shao PL, Chen HC, et al. Risk of respiratory syncytial virus infection in cyanotic congenital heart disease in a subtropical area. J Pediatr. 2016 Apr;171:25-30.e1. Abstract

64. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014 Aug;134(2):415-20.Full text  Abstract

65. Hu JR, Robinson JL. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J Pediatr. 2010 Nov;6(4):296-300.Full text  Abstract

66. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998 Sep;102(3 Pt 1):531-7. Abstract

67. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532-40. Abstract

68. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011 Sep;12(5):580-8. Abstract

69. Pons JM, Tebé C, Paladio N, et al. Meta-analysis of passive immunoprophylaxis in paediatric patients at risk of severe RSV infection. Acta Paediatr. 2011 Mar;100(3):324-9. Abstract

70. Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD006602.Full text  Abstract

71. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev. 2016;(7):CD007743.Full text  Abstract

72. American Academy of Pediatrics. Updated guidance: use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the 2021-2022 RSV season. Dec 2021 [internet publication].Full text

73. Garegnani L, Styrmisdóttir L, Roson Rodriguez P, et al. Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. Cochrane Database Syst Rev. 2021 Nov 16;11:CD013757.Full text  Abstract

74. Mansbach JM, Camargo CA Jr. Respiratory viruses in bronchiolitis and their link to recurrent wheezing and asthma. Clin Lab Med. 2009 Dec;29(4):741-55.Full text  Abstract

75. Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr. 2003 Nov;143(5 Suppl):S112-7. Abstract

76. Church NR, Anas NG, Hall CB, et al. Respiratory syncytial virus-related apnea in infants: demographics and outcome. Am J Dis Child. 1984 Mar;138(3):247-50. Abstract

77. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001 Sep 15;33(6):792-6.Full text  Abstract

78. Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019 Oct;74(10):986-993.Full text  Abstract

79. Moreira LP, Watanabe ASA, Camargo CN, et al. Respiratory syncytial virus evaluation among asymptomatic and symptomatic subjects in a university hospital in Sao Paulo, Brazil, in the period of 2009-2013. Influenza Other Respir Viruses. 2018 May;12(3):326-330.Full text  Abstract

80. Walsh EE, Falsey AR, Hennessey PA. Respiratory syncytial and other virus infections in persons with chronic cardiopulmonary disease. Am J Respir Crit Care Med. 1999 Sep;160(3):791-5.Full text  Abstract

81. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis. 2008 Feb 1;46(3):402-12.Full text  Abstract

82. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014 May 22;123(21):3263-8.Full text  Abstract

83. Bruning AHL, Leeflang MMG, Vos JMBW, et al. Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. Clin Infect Dis. 2017 Sep 15;65(6):1026-32.Full text  Abstract

84. Nicholson KG, Abrams KR, Batham S, et al. Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds. Health Technol Assess. 2014 May;18(36):1-274, vii-viii. Abstract

85. Krasinski K, LaCourture R, Holzman RS, et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission. J Pediatr. 1990 Jun;116(6):894-8. Abstract

86. Doan Q, Enarson P, Kissoon N, et al. Rapid viral diagnosis for acute febrile respiratory illness in children in the emergency department. Cochrane Database Syst Rev. 2014 Sep 15;(9):CD006452.Full text  Abstract

87. Ko F, Drews SJ. The impact of commercial rapid respiratory virus diagnostic tests on patient outcomes and health system utilization. Expert Rev Mol Diagn. 2017 Oct;17(10):917-31. Abstract

88. Chartrand C, Tremblay N, Renaud C, et al. Diagnostic accuracy of rapid antigen detection tests for respiratory syncytial virus infection: systematic review and meta-analysis. J Clin Microbiol. 2015 Dec;53(12):3738-49.Full text  Abstract

89. Simpson W, Hacking PM, Court SD, et al. The radiological findings in respiratory syncytial virus infection in children. II: the correlation of radiological categories with clinical and virological findings. Pediatr Radiol. 1974;2(3):155-60. Abstract

90. Simpson W, Hacking PM, Court SD, et al. The radiological findings in respiratory syncytial virus infection in children. Part I: definitions and interobserver variation in the assessment of abnormalities on the chest x-ray. Pediatr Radiol. 1974;2(2):97-100. Abstract

91. Friis B, Eiken M, Hornsleth A, et al. Chest x-ray appearances in pneumonia and bronchiolitis: correlation to virological diagnosis and secretory bacterial findings. Acta Paediatr Scand. 1990 Feb;79(2):219-25. Abstract

92. Chatzis O, Darbre S, Pasquier J, et al. Burden of severe RSV disease among immunocompromised children and adults: a 10 year retrospective study. BMC Infect Dis. 2018 Mar 6;18(1):111.Full text  Abstract

93. Hall CB. Respiratory syncytial virus: a continuing culprit and conundrum. J Pediatr. 1999 Aug;135(2 Pt 2):2-7. Abstract

94. Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J Pediatr. 1977 Mar;90(3):382-6. Abstract

95. Hall CB. Respiratory syncytial virus and sudden infant death. N Engl J Med. 1979 Jun 21;300(25):1440-1. Abstract

96. Anas N, Boettrich C, Hall CB, et al. The association of apnea and respiratory syncytial virus infection in infants. J Pediatr. 1982 Jul;101(1):65-8. Abstract

97. Kneyber MC, Brandenburg AH, de Groot R, et al. Risk factors for respiratory syncytial virus associated apnoea. Eur J Pediatr. 1998 Apr;157(4):331-5. Abstract

98. Willwerth BM, Harper MB, Greenes DS. Identifying hospitalized infants who have bronchiolitis and are at high risk for apnea. Ann Emerg Med. 2006 Oct;48(4):441-7. Abstract

99. Turner T, Wilkinson F, Harris C, et al. Evidence based guideline for the management of bronchiolitis. Aust Fam Physician. 2008 Jun;37(6 Spec No):6-13. Abstract

100. Stempel HE, Martin ET, Kuypers J, et al. Multiple viral respiratory pathogens in children with bronchiolitis. Acta Paediatr. 2009 Jan;98(1):123-6. Abstract

101. Weinberg GA, Erdman DD, Edwards KM, et al. Superiority of reverse-transcription polymerase chain reaction to conventional viral culture in the diagnosis of acute respiratory tract infections in children. J Infect Dis. 2004 Feb 15;189(4):706-10.Full text  Abstract

102. Koetz A, Nilsson P, Linden M, et al. Detection of human coronavirus NL63, human metapneumovirus and respiratory syncytial virus in children with respiratory tract infections in south-west Sweden. Clin Microbiol Infect. 2006 Nov;12(11):1089-96.Full text  Abstract

103. Mansbach JM, McAdam AJ, Clark S, et al. Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department. Acad Emerg Med. 2008 Feb;15(2):111-8.Full text  Abstract

104. Yuksel H, Yilmaz O, Akcali S, et al. Common viral etiologies of community acquired lower respiratory tract infections in young children and their relationship with long term complications [in Turkish]. Mikrobiyol Bul. 2008 Jul;42(3):429-35. Abstract

105. Position paper “RSV in preterm and ill infants”. The European Foundation for the Care of Newborn Infants. 2020 [internet publication].Full text

106. González de Dios J, Ochoa Sangrador C; Grupo de revision y panel de expertos de la Conferencia de Consenso del Proyecto aBREVIADo (BRonquiolitis-Estudio de Variabilidad, Idoneidad y ADecuación). Consensus conference on acute bronchiolitis (I): methodology and recommendations [in Spanish]. An Pediatr (Barc). 2010 Mar;72(3):221. Abstract

107. Caballero MT, Polack FP, Stein RT. Viral bronchiolitis in young infants: new perspectives for management and treatment. J Pediatr (Rio J). 2017 Nov - Dec;93(suppl 1):75-83.Full text  Abstract

108. O'Brien S, Craig S, Babl FE, et al; Paediatric Research in Emergency Departments International Collaborative (PREDICT) Network, Australasia. 'Rational use of high-flow therapy in infants with bronchiolitis. What do the latest trials tell us?' A Paediatric Research in Emergency Departments International Collaborative perspective. J Paediatr Child Health. 2019 Jul;55(7):746-52. Abstract

109. Combret Y, Prieur G, LE Roux P, et al. Non-invasive ventilation improves respiratory distress in children with acute viral bronchiolitis: a systematic review. Minerva Anestesiol. 2017 Jun;83(6):624-637.Full text  Abstract

110. Downes JJ, Wood DW, Striker TW, et al. Acute respiratory failure in infants with bronchiolitis. Anesthesiology. 1968 May-Jun;29(3):426-34. Abstract

111. Lodrup Carlsen KC, Carlsen KH. Inhaled nebulized adrenaline improves lung function in infants with acute bronchiolitis. Respir Med. 2000 Jul;94(7):709-14. Abstract

112. Modl M, Eber E, Weinhandl E, et al. Assessment of bronchodilator responsiveness in infants with bronchiolitis. A comparison of the tidal and the raised volume rapid thoracoabdominal compression technique. Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):763-8. Abstract

113. Sanchez I, De Koster J, Powell RE, et al. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. J Pediatr. 1993 Jan;122(1):145-51. Abstract

114. Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014 Jun 17;2014(6):CD001266.Full text  Abstract

115. Heikkilä P, Renko M, Korppi M. Hypertonic saline inhalations in bronchiolitis-A cumulative meta-analysis. Pediatr Pulmonol. 2018 Feb;53(2):233-242.Full text  Abstract

116. Everard ML, Hind D, Ugonna K, et al; SABRE Study Team. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax. 2014 Dec;69(12):1105-12.Full text  Abstract

117. Zhang L, Mendoza-Sassi RA, Klassen TP, et al. Nebulized hypertonic saline for acute bronchiolitis: a systematic review. Pediatrics. 2015 Oct;136(4):687-701. Abstract

118. von Lilienfeld-Toal M, Berger A, Christopeit M, et al. Community acquired respiratory virus infections in cancer patients: guideline on diagnosis and management by the Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology. Eur J Cancer. 2016 Nov;67:200-12.Full text  Abstract

119. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012 Apr;46(4):558-66. Abstract

120. Dignan FL, Clark A, Aitken C, et al; Haemato-oncology Task Force of the British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation; UK Clinical Virology Network. BCSH/BSBMT/UK Clinical Virology Network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol. 2016 May;173(3):380-93. Abstract

121. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011 Mar 10;117(10):2755-63.Full text  Abstract

122. Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014 Apr;16(2):242-50. Abstract

123. Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics. 1997 Dec;100(6):937-42. Abstract

124. Hemming VG, Rodriguez W, Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother. 1987 Dec;31(12):1882-6.Full text  Abstract

125. Levin D, Tribuzio M, Green-Wrzesinki T, et al. Empiric antibiotics are justified for infants with respiratory syncytial virus lower respiratory tract infection presenting with respiratory failure: a prospective study and evidence review. Pediatr Crit Care Med. 2010 May;11(3):390-5. Abstract

126. Farley R, Spurling GK, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age. Cochrane Database Syst Rev. 2014 Oct 9;(10):CD005189.Full text  Abstract

127. Ermers MJ, Rovers MM, van Woensel JB, et al. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial. BMJ. 2009 Mar 31;338:b897.Full text  Abstract

128. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev. 2013 Jun 4;(6):CD004878.Full text  Abstract

129. Alarcón-Andrade G, Cifuentes L. Should systemic corticosteroids be used for bronchiolitis? [in spa]. Medwave. 2018 May 7;18(3):e7207.Full text  Abstract

130. Alarcón-Andrade G, Cifuentes L. Do inhaled corticosteroids have a role for bronchiolitis? [in spa]. Medwave. 2018 Apr 17;18(2):e7183.Full text  Abstract

131. Enriquez A, Chu IW, Mellis C, et al. Nebulised deoxyribonuclease for viral bronchiolitis in children younger than 24 months. Cochrane Database Syst Rev. 2012 Nov 14;(11):CD008395.Full text  Abstract

132. Chalumeau M, Duijvestijn YC. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD003124.Full text  Abstract

133. Liet JM, Ducruet T, Gupta V, et al. Heliox inhalation therapy for bronchiolitis in infants. Cochrane Database Syst Rev. 2015 Sep 18;(9):CD006915.Full text  Abstract

134. Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med. 2008 Oct 15;178(8):854-60.Full text  Abstract

135. Chandelia S, Kumar D, Chadha N, et al. Magnesium sulphate for treating acute bronchiolitis in children up to two years of age. Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD012965.Full text  Abstract

136. Turner T, Wilkinson F, Harris C, et al. Evidence based guideline for the management of bronchiolitis. Aust Fam Physician. 2008 Jun;37(6 Spec No):6-13. Abstract

137. Acosta PL, Caballero MT, Polack FP. Brief history and characterization of enhanced respiratory syncytial virus disease. Clin Vaccine Immunol. 2015 Dec 16;23(3):189-95.Full text  Abstract

138. PATH. RSV vaccine and mAb snapshot. Oct 2018 [internet publication].Full text

139. Modjarrad K, Giersing B, Kaslow DC, et al; WHO RSV Vaccine Consultation Expert Group. WHO consultation on respiratory syncytial virus vaccine development report from a World Health Organization meeting held on 23-24 March 2015. Vaccine. 2016 Jan 4;34(2):190-7.Full text  Abstract

140. Mazur NI, Higgins D, Nunes MC, et al. The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018 Oct;18(10):e295-311. Abstract

141. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013 Jan 7;31(3):524-32. Abstract

142. Glenn GM, Fries LF, Thomas DN, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2016 Feb 1;213(3):411-22. Abstract

143. Falloon J, Ji F, Curtis C, et al. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine. 2016 May 27;34(25):2847-54.Full text  Abstract

144. Madhi SA, Polack FP, Piedra PA, et al. Respiratory syncytial virus vaccination during pregnancy and effects in infants. N Engl J Med. 2020 Jul 30;383(5):426-39.Full text  Abstract

145. US National Institutes of Health; ClinicalTrials.gov. A study to determine the safety and efficacy of the RSV F vaccine to protect infants via maternal immunization: ClinicalTrials.gov identifier:NCT02624947. December 2015 [internet publication].Full text

146. August A, Glenn GM, Kpamegan E, et al. A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017 Jun 27;35(30):3749-59.Full text  Abstract

147. US National Institutes of Health; ClinicalTrials.gov. A study to evaluate the efficacy of an RSV F vaccine in older adults: ClinicalTrials.gov identifier:NCT02608502. November 2015 [internet publication].Full text

148. Langley JM, Aggarwal N, Toma A, et al. A randomized, controlled, observer-blinded phase 1 study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis. 2017 Jan 1;215(1):24-33.Full text  Abstract

149. ClinicalTrials.gov. A study of an Ad26.RSV.preF-based regimen in the prevention of reverse transcriptase polymerase chain reaction (RT-PCR)-confirmed respiratory syncytial virus (RSV)-mediated lower respiratory tract disease in adults aged 65 years and older. 25 Sep 2020 [internet publication].Full text

150. Falloon J, Talbot HK, Curtis C, et al. Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses. Clin Vaccine Immunol. 2017 Sep 5;24(9):e00157-17.Full text  Abstract

151. Griffin MP, Khan AA, Esser MT, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017 Feb 23;61(3):e01714-16.Full text  Abstract

152. Falloon J, Yu J, Esser MT, et al. An adjuvanted, postfusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis. 2017 Dec 12;216(11):1362-70.Full text  Abstract

153. Griffin MP, Yuan Y, Takas T, et al; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020 Jul 30;383(5):415-25.Full text  Abstract

154. Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022 Mar 3;386(9):837-46. Abstract

155. Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, et al. Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects. Clin Pharmacokinet. 2017 Nov;56(11):1331-42. Abstract

156. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014 Aug 21;371(8):711-22.Full text  Abstract

157. Robinson J, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. May 2016 [internet publication].Full text

158. O'Brien S, Borland ML, Cotterell E, et al. Australasian bronchiolitis guideline. J Paediatr Child Health. 2019 Jan;55(1):42-53.Full text  Abstract

159. South Australian Paediatric Clinical Practice Guidelines Bronchiolitis in Children. Department for Health and Wellbeing, Government of South Australia. 2018 [internet publication].Full text

160. Fujiogi M, Goto T, Yasunaga H, et al. Trends in bronchiolitis hospitalizations in the United States: 2000-2016. Pediatrics. 2019 Dec;144(6):e20192614.Full text  Abstract

161. Sung RY, Murray HG, Chan RC, et al. Seasonal patterns of respiratory syncytial virus infection in Hong Kong: a preliminary report. J Infect Dis. 1987 Sep;156(3):527-8. Abstract

162. Scheltema NM, Gentile A, Lucion F, et al. Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series. Lancet Glob Health. 2017 Oct;5(10):e984-91.Full text  Abstract

163. Driscoll AJ, Arshad SH, Bont L, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine. 2020 Mar 4;38(11):2435-48.Full text  Abstract

164. Sigurs N, Bjarnason R, Sigurbergsson F, et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000 May;161(5):1501-7.Full text  Abstract

165. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999 Aug 14;354(9178):541-5. Abstract

166. Lu S, Hartert TV, Everard ML, et al. Predictors of asthma following severe respiratory syncytial virus (RSV) bronchiolitis in early childhood. Pediatr Pulmonol. 2016 Dec;51(12):1382-92. Abstract

167. Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. Lancet Respir Med. 2018 Apr;6(4):257-64. Abstract

168. Hall CB, Douglas RG Jr. Nosocomial respiratory syncytial viral infections: should gowns and masks be used? Am J Dis Child. 1981 Jun;135(6):512-5. Abstract

169. Gala CL, Hall CB, Schnabel KC, et al. The use of eye-nose goggles to control nosocomial respiratory syncytial virus infection. JAMA. 1986 Nov 21;256(19):2706-8. Abstract

170. Agah R, Cherry JD, Garakian AJ, et al. Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections: routine isolation procedure vs routine procedure supplemented by use of masks and goggles. Am J Dis Child. 1987 Jun;141(6):695-7. Abstract

171. Leclair JM, Freeman J, Sullivan BF, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med. 1987 Aug 6;317(6):329-34. Abstract

172. Smith JD, MacDougall CC, Johnstone J, et al. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ. 2016 May 17;188(8):567-74.Full text  Abstract

Use of this content is subject to our disclaimer